The demand for statin: The effect of copay on utilization and compliance

Health Economics

Volumn 17, Issue 1, 2008, Pages 83-97

  Thiebaud, Patrick ^a   Patel, Bimal V ^b   Nichol, Michael B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MedImpact Healthcare Systems Inc   (United States)

Author keywords

Compliance; Copay; Drug demand; Statin; Utilization

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; POISSON DISTRIBUTION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

COMORBIDITY; DEDUCTIBLES AND COINSURANCE; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PATIENT COMPLIANCE;

EID: 38949121258     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1245     Document Type: Article

References (52)

1. Abughosh S, Kogut SJ, Andrade SE, Larrat EP, Gurwitz JH. 2004. Persistence with lipid-lowering therapy: influence of the type of lipid lowering agent and drug benefit plan option in elderly patients. Journal of Managed Care Pharmacy 10(5): 404-411.
2. American Heart Association. 2004. Heart Disease and Stroke Statistics - 2005 Update. www.americanheart.org (10 January 2005).
3. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. 1998. Persistence of use of lipid-lowering medications. A cross-national study. Journal of the American Medical Association 279: 1458-1462.
4. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. 2002. Long-term persistence in use of statin therapy in elderly patients. Journal of the American Medical Association 288: 455-461.
5. Blumberg LJ, Nichols LM. 2004. Why are so many Americans uninsured? In Health Policy and the Uninsured, McLaughlin CG (ed.). The Urban Institute Press: Washington, DC.
6. Bruckert E, Simonetta C, Giral P, The CREOLE Study Team. 1999. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. Journal of Clinical Epdiemiology 52(6): 589-594.
7. Bymark L, Waite K. 2001. Prescription Drug Use and Expenditures in California: Key Trends and Drivers. California Health Care Foundation, CA.
8. Cameron AC, Trivedi PK. 1998. Regression Analysis of Count Data. Cambridge University Press: Cambridge, UK; 275-300.
9. Cameron AC, Trivedi PK, Milne F, Piggott J. 1988. A microeconometric model of the demand for health care and health insurance in Australia. Review of Economic Studies 55(1): 85-106.
10. Chamberlain G. 1980. Analysis of covariance with qualitative data. Review of Economics Studies 47: 225-238.
11. Chamberlain G. 1985. Heterogeneity, omitted variable bias, and duration dependence. In Longitudinal Analysis of Labor Market Data, Heckman J, Singer B (eds). Cambridge University Press: Cambridge; 3-38.
12. Dor A, Encinosa W. 2004. Does cost sharing affect compliance? The case of prescription drugs. NBER Working Paper No. 10738.
13. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. 2004. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? Journal of General Internal Medicine 19: 638-645.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III). Journal of the American Medical Association 285: 2486-2497.
15. Express Scripts Drug Trend Report 2003. 2004. Expressed Scripts. www.express-scripts.com (3 February 2005).
16. Fairman KA, Motheral BR, Henderson RR. 2003. Retrospective long-term follow up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clinical Therapeutics 25(12): 3147-3161.
17. Fendrick AM, Smith DG, Chernew ME, Sonali NS. 2001. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. American Journal of Managed Care 7(9): 861-867.
18. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. 2003. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Medical Care 41(1): 84-99.
19. Gabel J, Claxton G, Holve E et al. 2003. Health benefits in 2003: premiums reach thirteen-year high as employers adopt new forms of cost sharing. Health Affairs 22(5): 117-126.
20. Gabel J, Levitt L, Holve E et al. 2002. Job-based health benefits in 2002: some important trends. Health Affairs 21(5): 143-151.
21. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM. 2004. Pharmacy benefit and the use of drugs by the chronically ill. Journal of the American Medical Association 291(19): 2344-2350.
22. Green WH. 1997. Econometric Analysis (third edn). Prentice-Hall: Englewood Cliffs, NJ; 418-446.
23. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ and Coordinating Committee of the National Cholesterol Education Program. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44(3): 720-732.
24. Hausman J. 1978. Specification tests in econometrics. Econometrica 46: 1251-1271.
25. Heeshen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. 2002. Withdrawal of statins increases event rates in patients with acute coronary syndrome. Circulation 105: 1446-1452.
26. Hiatt JG, Shamsie S, Schectman G. 1999. Discontinuation rates of cholesterol-lowering medications: implications for primary care. American Journal of Managed Care 5(4): 437-444.
27. Huskamp HA, Deverka PA, Epstein AM et al. 2003. The effect of incentive-based formularies on prescription-drug utilization and spending. New England Journal of Medicine 349: 2224-2232.
28. IMS Retail Drug Monitor. 2004. IMS Health. IMS Retail Drug Monitor, http://www.imshealth.com/vgn/images/portal/cit_40000873/33/57/ 71618386IMS_DRUGMON_DEC04updated.pdf (2 February 2005).
29. Jackevicius CA, Mamdani M, Tu JV. 2002. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Journal of the American Medical Association 288: 462-467.
30. Johnson RE, Goodman MJ, Hornbrook MC et al. 1997. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Medical Care 35: 1119-1131.
31. Joyce GF, Escarce JJ, Solomon MD et al. 2002. Employer drug benefit plan and spending on prescription drugs. Journal of the American Medical Association 288: 1733-1739.
32. Kaiser Family Foundation. 2005. Employer Health Benefit 2004 Annual Survey. Accessed at www.kff.org (2 February 2005).
33. Kleinke JD. 2000. Just what the HMO ordered: the paradox of increasing drug costs. Health Affairs 19(2): 78-91.
34. Lee MJ. 2002. Panel Data Econometrics. Methods-of-Moments and Limited Dependent Variables. Academic Press/Elsevier Science: San Diego, CA; 81-114.
35. Lillard LA, Rogowski J, Kington R. 1999. Insurance coverage for prescription drugs: the effect on use and expenditures in the medicaid population. Medical Care 37(7): 926-936.
36. McDermott MM, Schmitt B, Wallner E. 1997. Impact of medication non-adherence on coronary heart disease outcomes: a critical review. Archives of Internal Medicine 157: 1921-1929.
37. National Institute of Health, National Heart, Lung, and Blood Institute. 2004. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases.
38. Nelson AA, Reeder CE, Dickson WM. 1984. The effect of a medicaid drug copayment program on the utilization and cost of prescription services. Medical Care 22(8): 724-735.
39. Rathouz PJ. 2004. Fixed effects models for longitudinal binary data with drop-outs missing at random. Statistica Sinica 14: 969-988.
40. Rector TS, Finch MD, Danzon PM et al. 2003. Effect of tiered prescription copayments on the use of preferred brand medications. Medical Care 41(3): 398-406.
41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New England Journal of Medicine 336: 1001-1009.
42. Scandinavian Simvastatin Survival Study (4S) Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389.
43. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158.
44. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. 2005. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in managed care population. American Journal of Managed Care 11: 306-312.
45. Smith DG. 1993. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 30: 189-198.
46. Strunk BC, Ginsburg PB. 2004. Tracking health care costs: trends turn downward in 2003. Health Affairs w4: 354-362.
47. Stuart B, Grana J. 1998. Ability to pay and decision to medicate. Medical Care 36(2): 202-211.
48. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 339(19): 1349-1357.
49. Thomas CL, Wallack SS, Lee S, Ritter GA. 2002. Impact of health plan design and management on retirees' prescription drug use and spending, 2001. Health Affairs 21(6): 408-419.
50. Wei L, Wang J, Thompson P, Wong S, Struthers AD, McDonalds TM. 2002. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 88: 229-233.
51. Wooldridge JM. 1999. Distribution-free estimation of some nonlinear panel data models. Journal of Econometrics 90: 77-97.
52. Wooldridge JM. 2003. Econometric Analysis of Cross Section and Panel Data. MIT Press: Cambridge, MA; 247-339.